Serum level of Total Antioxidant Status and Malondialdehyde in the Patients with Polycystic Ovarian Syndrome: a Comparative Study

Authors

  • Bibek Pun Magar Assistant Professor, Department of Clinical Biochemistry, Karnali academy of health sciences, Jumla Nepal https://orcid.org/0000-0003-0887-6405
  • Dilli Pun Magar Assistant Professor, Department of Physiology, Karnali Academy of Health Sciences, Jumla, Nepal
  • Kapil Amgain Associate Professor, HOD of Department Clinical Anatomy, Karnali Academy of Health Sciences
  • Keshavraj Joshi Lecturer, Department of Biochemistry, Khaptad Medical Studies and Health Sciences, Council for Technical Education and Vocational Training (CTEVT)
  • Niranjan Satyal Consultant Biochemist, Department of Biochemistry,Chaurjahari Municipality Laboratory, West- Rukum, Nepal
  • Jharendra Bahadur Oli Pathology Technician,Department of Laboratory, Royal Hobart Hospital, Australia

Keywords:

Antioxidants, Infertility, Oxidative biomarker, Oxidative stress, AMH, TAS, PCOD, Polycystic ovary diseases

Abstract

Background: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder in women of reproductive age and a major cause of infertility. Anti- Mullerian Hormone (AMH), a valid marker of ovarian function, is used for the diagnosis of PCOS. The aim of this study is to assess the serum level of total antioxidant status (TAS) and malondialdehyde (MDA) in the premenopausal women with PCOS.

Methods: A cross-sectional analytical study was conducted at Padmashree Diagnostics, Department of Gynecology, India from April 2016 to March 2017. Census method was used to select the samples. The oxidative stress was measured by measuring the level of TAS and MDA. The data was recorded in structured proforma and and enter in SPSS version 16.0. The data were expressed in frequency, percentage, mean and standard deviation and the results obtained were analyzed using pearson’s correlation and student’s t-test. The p-value less than 0.05 was taken as statistically significant.

Results: The measured serum AMH level among the patients with PCOS was within normal range in 67.5% (27) and above normal range in 32.5% (13). The serum TAS level in normal AMH group was 814.0 + 291 µMol/L and in above normal range group was 720 + 240 µMol/L, (p <0.001). Similarly, the serum level of MDA in normal AMH group was 6.64 + 0.21 µMol/L, and in above normal range group was 8.78 + 0.22 µMol/L (p = 0.01). The measured level of AMH was significantly associated with the increased level of MDA (p<0.001) and decreased level of TAS (p<0.001). The measured MDA level in high AMH group did show statistically significant than the normal AMH group.

Conclusions: Serum level of TAS and MDA along with AMH are valuable diagnostic biomarker for the diagnosis of PCOS in the resource poor settings where ultrasound facility is unavailable.

DOI: https://doi.org/10.46405/ejms.v3i2.367

Downloads

Download data is not yet available.
Abstract
0
Download Full Text PDF
0

Downloads

Published

2021-12-30

How to Cite

Magar , B. P., Magar , D. P., Amgain, K., Joshi, K., Satyal , N., & Oli , J. B. (2021). Serum level of Total Antioxidant Status and Malondialdehyde in the Patients with Polycystic Ovarian Syndrome: a Comparative Study . Europasian Journal of Medical Sciences, 5(2). Retrieved from https://nepjol.info./index.php/ejms/article/view/77269

Issue

Vol. 5 No. 2 (2021): Europasian Journal of Medical Sciences (EJMS) | 2021 (July - December) Issue 6

Section

Original Articles

License

Copyright (c) 2025 Bibek Pun Magar , Dilli Pun Magar , Kapil Amgain, Keshavraj Joshi, Niranjan Satyal , Jharendra Bahadur Oli

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The author(s) retain the ownership of the copyrights for their work published in EJMS without any restrictions. Upon submission, the author(s) grants EJMS a license to publish, including to display, store, copy, and reuse the published content.

License to Publish
By submitting a manuscript to EJMS, the author(s) grant the journal a non-exclusive license to:

  • Publish and distribute the content in all formats, media, and platforms (both existing and future), while identifying EJMS as the original publisher.
  • Reproduce, display, and store the content in both print and online formats, including institutional and digital repositories.
  • Translate, adapt, and summarize the work, including reprints, extracts, and abstracts.
  • Develop derivative works based on the original content.
  • Include the work in electronic databases and provide links to third-party materials.

Creative Commons Licensing
In addition to EJMS’s publishing rights, authors grant third parties the right to use, share, and distribute their work under the Creative Commons Attribution 4.0 (CC BY 4.0) International License. This allows unrestricted use of the content, provided proper attribution is given to the original author(s) and the journal.